How compounded peptides are actually made

Compounding is making a medication to order

A compounding pharmacy prepares a medication rather than dispensing one that arrived finished from a manufacturer. It mixes ingredients into a specific strength, form or combination, and then labels and supplies it.

The practice is old and legitimate. It exists to solve real problems. A patient cannot swallow a tablet. A child needs a smaller strength than any product offers. Someone reacts to a dye in the commercial version, or a drug is in shortage.

What compounding is not is manufacturing. A manufacturer submits a product to the FDA, which reviews the evidence for safety and effectiveness and inspects how the product is made. A compounded preparation goes through none of that. It has not been reviewed by the FDA for safety, effectiveness or quality, whatever the pharmacy's own standards are.

That is the single most important sentence about this entire market, and it is true of every compounded peptide, from every pharmacy, sold by every provider.

Two categories, named after sections of a law

US law splits compounders into two groups. The names come from the sections of the Federal Food, Drug, and Cosmetic Act that describe them, which is why the industry talks in numbers that mean nothing to a patient.

A 503A pharmacy is a traditional compounding pharmacy. A 503B facility is an outsourcing facility. They are not two grades of the same thing, and neither one is a lesser version of the other. They are built for different jobs and are overseen differently.

What a 503A pharmacy is

A 503A pharmacy compounds for one identified patient at a time, against a prescription written for that person. That patient-specific requirement is the defining feature of the category.

In exchange for staying inside those limits, a 503A pharmacy is exempt from several requirements that apply to drug manufacturers. It does not need FDA approval for what it makes. It does not have to carry the full directions-for-use labeling a commercial product carries. And it is not required to operate under the federal current good manufacturing practice rules that govern factories.

Oversight comes mainly from the state board of pharmacy that licenses it. Boards set standards, issue licenses and inspect. The FDA retains authority as well, but the day-to-day regulator of a 503A pharmacy is the state.

This is the category most telehealth peptide prescriptions run through, because the model matches: one patient, one prescriber, one prescription.

What a 503B outsourcing facility is

A 503B outsourcing facility can compound in batches without a prescription naming an individual patient. That is what makes it possible to supply a clinic with stock on the shelf.

The trade for that freedom is a heavier set of obligations. A 503B facility registers with the FDA. It must comply with current good manufacturing practice, the same framework that governs commercial drug production. It is subject to FDA inspection on a risk-based schedule, and it reports adverse events to the agency.

The category exists because of a disaster. Contaminated injections prepared by a compounding pharmacy caused a national fungal meningitis outbreak, and people died. Congress responded by creating the outsourcing facility category in the Drug Quality and Security Act, so that large-scale sterile compounding would sit under federal manufacturing rules rather than outside them.

A 503B facility being held to manufacturing practice standards is a meaningful difference. It is still not FDA approval of the product it makes.

Neither category means the drug was approved

This is where marketing gets slippery, so it is worth stating flatly. "FDA-registered" is not "FDA-approved." Registration means the facility told the agency it exists and is subject to inspection. Approval means a specific product was reviewed and cleared for a specific use.

No compounded preparation is an FDA-approved drug. A 503B facility making sterile injectables under manufacturing rules is producing an unapproved drug carefully. That is genuinely better than producing one carelessly, and it is still an unapproved drug.

Any site or clinic that presents registration, inspection or licensure as though it were approval is trading on a distinction the reader is not expected to know.

Which substances may be compounded at all

A pharmacy cannot lawfully compound with any powder it likes. The starting material has to qualify, and the rules for qualifying are specific.

In general terms, a substance qualifies in one of three ways. It is a component of an FDA-approved drug. It has a monograph in the official pharmacopeia setting out its standards. Or the FDA has placed it on the list of substances permitted for compounding. Outsourcing facilities work from their own separate list.

For several peptides, whether they qualify is exactly the question that is contested rather than settled. That question is tracked per compound elsewhere on this site, with the current standing stated for each one. No outcome is predicted here, and nothing about any specific compound is characterized in this article.

The practical point for a reader is simply that eligibility is a real gate with real rules, and it is upstream of everything else. A pharmacy that is licensed and inspected is still not permitted to compound a substance that does not qualify.

Why "which pharmacy" is the disclosure that matters

The pharmacy is the party that actually makes the thing going into the syringe. The telehealth brand designs the website, runs the intake and bills the card. It usually does not compound anything.

So the pharmacy name is the answer to the only question that reaches the vial. It tells you which state licensed the facility, which category it operates in, and which regulator holds its inspection record. A named pharmacy can be looked up in a state board license database by anyone.

A provider that does not name its pharmacy removes every one of those handles at once. The buyer is left assessing a brand rather than a facility, and a brand can change suppliers without telling anyone. This is why the site treats "names its compounding pharmacy" as a disclosure worth scoring, rather than a detail.

It is a disclosure standard, not an accusation. A provider that declines to name its pharmacy has not been shown to be using a bad one. It has declined to let the question be asked, which is a different failing and a checkable one.

What a named pharmacy does not prove

Naming a pharmacy establishes less than it might seem, and overreading it is its own error.

It does not mean the preparation was tested for potency or sterility, unless the provider says testing is done and says who did it. It does not mean the compound is approved, because compounded preparations are not. It does not mean the pharmacy has a clean inspection history, only that the history can now be found. And it does not mean the pharmacy will still be the supplier next quarter.

What it does is convert an unanswerable question into an answerable one. That is the whole value of it. Every further question a buyer might ask about who made the product depends on first knowing who made the product.